

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Lee's Pharmaceutical Holdings Limited

李氏大藥廠控股有限公司*

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 950)

VOLUNTARY ANNOUNCEMENT – ALISKIREN COMBINED WITH NIFEDIPINE OBTAINED APPROVAL FROM WEST CHINA HOSPITAL BIOMEDICAL ETHICS COMMITTEE OF SICHUAN UNIVERSITY TO CONDUCT CLINICAL TRIAL ON THE TREATMENT OF HYPERTENSION PATIENT WITH CONFIRMED COVID-19 PNEUMONIA

This announcement is made by the board of directors (the “**Board**”) of Lee’s Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries as the “**Group**”) on a voluntary basis.

The investigator-initiated clinical trial, led by Dr. Luo Feng Ming (羅鳳鳴), the chief physician of Division of Respiratory & Critical Care Medicine of West China Hospital, Sichuan University, to evaluate efficacy and safety of Aliskiren combined with Nifedipine to treat hypertension patient with confirmed COVID-19 pneumonia, has obtained approval from West China Hospital Biomedical Ethics Committee of Sichuan University on 3 March 2020.

According to an article “Comorbidity and its impact on 1,590 patients with COVID-19 in China: A Nationwide Analysis” recently published by respiratory disease scientist Nanshan Zhong and other experts, hypertension is the most common comorbidity (16.9%) among the patients with confirmed COVID-19 pneumonia, as compared to other comorbidities such as cardiovascular diseases, cerebrovascular diseases, diabetes, hepatitis B infections, chronic obstructive pulmonary disease, chronic kidney diseases, malignancy and immunodeficiency.

Aliskiren is currently the only renin inhibitor drug in the world that is approved for marketing and the indication for Aliskiren is treatment of essential hypertension. In December 2017, the Group obtained exclusive agency and sales rights of Aliskiren tablet (trade name: Rasilez®) in Mainland China, Hong Kong, Macau and Taiwan.

* For identification purposes only

The Company will keep track of this clinical trial and will update on its progress on a timely manner.

By order of the Board of
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 10 March 2020

As at the date of this announcement, Ms. Lee Siu Fong (Chairman), Ms. Leelalertsuphakun Wanee and Dr. Li Xiaoyi are executive directors of the Company, Mr. Simon Miles Ball is a non-executive director of the Company, Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive directors of the Company.